|
Orthologous residues
|
|
P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A (rat): T180‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
phospho-antibody, western blotting
|
|
Disease tissue studied:
brain cancer, glioblastoma, glioblastoma multiforme, glioma
|
|
Relevant cell lines - cell types - tissues:
mononuclear, U373 MG (glial) [CD14 (human), transfection]
|
|
Cellular systems studied:
cell lines, primary cells
|
|
Species studied:
human
|
|
Upstream Regulation
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
LPS
|
|
|
|
increase
|
|
|
dexamethasone
|
LPS
|
|
|
inhibit treatment-induced increase
|
|
|
|
LPS
|
MKP-1 (human)
|
|
inhibit treatment-induced increase
|
|
|
poly(I-C)
|
|
|
|
increase
|
|
|
dexamethasone
|
poly(I-C)
|
|
|
inhibit treatment-induced increase
|
|
|